CA2742088A1 - Anticorps qui lient les proteines psca pour le diagnostic du cancer - Google Patents

Anticorps qui lient les proteines psca pour le diagnostic du cancer Download PDF

Info

Publication number: CA2742088A1
Authority: CA; Canada
Prior art keywords: psca; antibody; protein; cancer; antibodies
Prior art date: 2004-05-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2742088A

Other languages

English (en)

Inventor

Jean Gudas

Aya Jakobovits

Xiao-Chi Jia

Robert Kendall Morrison

Karen Jane Meyrick Morrison

Hui Shao

Pia M. Challita-Eid

Arthur B. Raitano

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Agensys Inc

Original Assignee

Agensys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-28

Filing date

2005-05-17

Publication date

2005-12-15

2004-05-28 Priority claimed from US10/857,484 external-priority patent/US7622564B2/en

2005-05-17 Application filed by Agensys Inc filed Critical Agensys Inc

2005-05-17 Priority claimed from CA2567449A external-priority patent/CA2567449C/fr

2005-12-15 Publication of CA2742088A1 publication Critical patent/CA2742088A1/fr

Status Abandoned legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 229
206010028980 Neoplasm Diseases 0.000 title claims abstract description 209
102000004169 proteins and genes Human genes 0.000 title claims abstract description 202
201000011510 cancer Diseases 0.000 title claims abstract description 121
238000003745 diagnosis Methods 0.000 title description 8
102100036735 Prostate stem cell antigen Human genes 0.000 claims abstract description 642
239000012634 fragment Substances 0.000 claims abstract description 64
101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims abstract description 31
210000004027 cell Anatomy 0.000 claims description 178
238000000034 method Methods 0.000 claims description 176
125000003275 alpha amino acid group Chemical group 0.000 claims description 97
230000027455 binding Effects 0.000 claims description 81
108091007433 antigens Proteins 0.000 claims description 80
102000036639 antigens Human genes 0.000 claims description 80
239000000427 antigen Substances 0.000 claims description 79
239000002157 polynucleotide Substances 0.000 claims description 61
102000040430 polynucleotide Human genes 0.000 claims description 61
108091033319 polynucleotide Proteins 0.000 claims description 61
239000000523 sample Substances 0.000 claims description 57
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 49
206010060862 Prostate cancer Diseases 0.000 claims description 48
239000000203 mixture Substances 0.000 claims description 47
238000003556 assay Methods 0.000 claims description 44
239000013598 vector Substances 0.000 claims description 44
210000002307 prostate Anatomy 0.000 claims description 38
239000012472 biological sample Substances 0.000 claims description 29
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 19
239000000126 substance Substances 0.000 claims description 18
206010005003 Bladder cancer Diseases 0.000 claims description 16
201000005112 urinary bladder cancer Diseases 0.000 claims description 16
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 14
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 13
208000008443 pancreatic carcinoma Diseases 0.000 claims description 13
210000004408 hybridoma Anatomy 0.000 claims description 11
201000002528 pancreatic cancer Diseases 0.000 claims description 11
239000003550 marker Substances 0.000 claims description 10
238000012258 culturing Methods 0.000 claims description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
239000013068 control sample Substances 0.000 claims 4
230000014509 gene expression Effects 0.000 abstract description 103
230000001225 therapeutic effect Effects 0.000 abstract description 39
210000001744 T-lymphocyte Anatomy 0.000 abstract description 21
230000003053 immunization Effects 0.000 abstract description 16
238000002649 immunization Methods 0.000 abstract description 13
230000000069 prophylactic effect Effects 0.000 abstract description 9
230000024932 T cell mediated immunity Effects 0.000 abstract description 8
230000028996 humoral immune response Effects 0.000 abstract description 3
101710120463 Prostate stem cell antigen Proteins 0.000 description 685
108090000765 processed proteins & peptides Proteins 0.000 description 204
235000018102 proteins Nutrition 0.000 description 192
102000004196 processed proteins & peptides Human genes 0.000 description 122
241000282414 Homo sapiens Species 0.000 description 106
235000001014 amino acid Nutrition 0.000 description 68
108020004414 DNA Proteins 0.000 description 66
229940024606 amino acid Drugs 0.000 description 65
150000007523 nucleic acids Chemical group 0.000 description 65
150000001413 amino acids Chemical class 0.000 description 64
238000011282 treatment Methods 0.000 description 60
102000039446 nucleic acids Human genes 0.000 description 56
108020004707 nucleic acids Proteins 0.000 description 56
108020004999 messenger RNA Proteins 0.000 description 53
210000001519 tissue Anatomy 0.000 description 53
229920001184 polypeptide Polymers 0.000 description 49
229960005486 vaccine Drugs 0.000 description 46
241001465754 Metazoa Species 0.000 description 44
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 42
239000000047 product Substances 0.000 description 42
230000002163 immunogen Effects 0.000 description 41
239000002299 complementary DNA Substances 0.000 description 35
201000010099 disease Diseases 0.000 description 30
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
230000000694 effects Effects 0.000 description 29
229940127089 cytotoxic agent Drugs 0.000 description 28
108020004705 Codon Proteins 0.000 description 27
239000003795 chemical substances by application Substances 0.000 description 26
210000002443 helper t lymphocyte Anatomy 0.000 description 25
230000028993 immune response Effects 0.000 description 25
239000002773 nucleotide Substances 0.000 description 24
125000003729 nucleotide group Chemical group 0.000 description 24
238000011579 SCID mouse model Methods 0.000 description 23
238000002512 chemotherapy Methods 0.000 description 23
238000001514 detection method Methods 0.000 description 23
230000005855 radiation Effects 0.000 description 23
238000006467 substitution reaction Methods 0.000 description 23
230000000875 corresponding effect Effects 0.000 description 22
241000699670 Mus sp. Species 0.000 description 21
108020004459 Small interfering RNA Proteins 0.000 description 21
230000012010 growth Effects 0.000 description 21
239000003814 drug Substances 0.000 description 20
230000000295 complement effect Effects 0.000 description 19
210000004443 dendritic cell Anatomy 0.000 description 19
102000050405 human PSCA Human genes 0.000 description 19
241001529936 Murinae Species 0.000 description 18
239000002246 antineoplastic agent Substances 0.000 description 18
230000005847 immunogenicity Effects 0.000 description 18
210000004881 tumor cell Anatomy 0.000 description 18
108091028043 Nucleic acid sequence Proteins 0.000 description 17
239000003153 chemical reaction reagent Substances 0.000 description 17
150000001875 compounds Chemical class 0.000 description 17
230000034994 death Effects 0.000 description 17
231100000517 death Toxicity 0.000 description 17
230000006870 function Effects 0.000 description 17
230000005764 inhibitory process Effects 0.000 description 17
239000003446 ligand Substances 0.000 description 17
210000000056 organ Anatomy 0.000 description 17
230000004614 tumor growth Effects 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
238000013459 approach Methods 0.000 description 16
230000004071 biological effect Effects 0.000 description 16
241000124008 Mammalia Species 0.000 description 15
230000001404 mediated effect Effects 0.000 description 15
230000004048 modification Effects 0.000 description 15
238000012986 modification Methods 0.000 description 15
150000003384 small molecules Chemical class 0.000 description 15
238000002560 therapeutic procedure Methods 0.000 description 15
238000004458 analytical method Methods 0.000 description 14
230000004044 response Effects 0.000 description 14
238000012216 screening Methods 0.000 description 14
238000001356 surgical procedure Methods 0.000 description 14
206010009944 Colon cancer Diseases 0.000 description 13
108060003951 Immunoglobulin Proteins 0.000 description 13
108091034117 Oligonucleotide Proteins 0.000 description 13
238000005516 engineering process Methods 0.000 description 13
238000001943 fluorescence-activated cell sorting Methods 0.000 description 13
102000018358 immunoglobulin Human genes 0.000 description 13
238000000338 in vitro Methods 0.000 description 13
230000001965 increasing effect Effects 0.000 description 13
-1 peptidyl phosphonates Chemical class 0.000 description 13
239000013612 plasmid Substances 0.000 description 13
238000001959 radiotherapy Methods 0.000 description 13
206010006187 Breast cancer Diseases 0.000 description 12
208000026310 Breast neoplasm Diseases 0.000 description 12
206010027476 Metastases Diseases 0.000 description 12
125000000539 amino acid group Chemical group 0.000 description 12
230000000692 anti-sense effect Effects 0.000 description 12
230000001419 dependent effect Effects 0.000 description 12
210000004072 lung Anatomy 0.000 description 12
238000011830 transgenic mouse model Methods 0.000 description 12
239000002671 adjuvant Substances 0.000 description 11
230000010261 cell growth Effects 0.000 description 11
239000002254 cytotoxic agent Substances 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
238000011534 incubation Methods 0.000 description 11
230000002401 inhibitory effect Effects 0.000 description 11
238000010253 intravenous injection Methods 0.000 description 11
210000001165 lymph node Anatomy 0.000 description 11
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
108010072866 Prostate-Specific Antigen Proteins 0.000 description 10
102100038358 Prostate-specific antigen Human genes 0.000 description 10
230000004075 alteration Effects 0.000 description 10
239000003098 androgen Substances 0.000 description 10
238000009175 antibody therapy Methods 0.000 description 10
210000000612 antigen-presenting cell Anatomy 0.000 description 10
102000037865 fusion proteins Human genes 0.000 description 10
108020001507 fusion proteins Proteins 0.000 description 10
229940022353 herceptin Drugs 0.000 description 10
238000009396 hybridization Methods 0.000 description 10
210000000987 immune system Anatomy 0.000 description 10
210000003734 kidney Anatomy 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
230000009261 transgenic effect Effects 0.000 description 10
108700028369 Alleles Proteins 0.000 description 9
241000699660 Mus musculus Species 0.000 description 9
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
238000012217 deletion Methods 0.000 description 9
230000037430 deletion Effects 0.000 description 9
238000003780 insertion Methods 0.000 description 9
230000037431 insertion Effects 0.000 description 9
238000007912 intraperitoneal administration Methods 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
210000002966 serum Anatomy 0.000 description 9
241000894007 species Species 0.000 description 9
230000008685 targeting Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 9
229940124597 therapeutic agent Drugs 0.000 description 9
239000003053 toxin Substances 0.000 description 9
231100000765 toxin Toxicity 0.000 description 9
108700012359 toxins Proteins 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
206010033128 Ovarian cancer Diseases 0.000 description 8
206010061535 Ovarian neoplasm Diseases 0.000 description 8
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
230000003321 amplification Effects 0.000 description 8
229940022399 cancer vaccine Drugs 0.000 description 8
238000011161 development Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
230000004927 fusion Effects 0.000 description 8
230000013595 glycosylation Effects 0.000 description 8
238000006206 glycosylation reaction Methods 0.000 description 8
238000003384 imaging method Methods 0.000 description 8
230000003993 interaction Effects 0.000 description 8
230000036210 malignancy Effects 0.000 description 8
229930182817 methionine Natural products 0.000 description 8
238000012544 monitoring process Methods 0.000 description 8
230000035772 mutation Effects 0.000 description 8
238000003199 nucleic acid amplification method Methods 0.000 description 8
239000002245 particle Substances 0.000 description 8
238000011160 research Methods 0.000 description 8
238000003757 reverse transcription PCR Methods 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
125000006850 spacer group Chemical group 0.000 description 8
238000005406 washing Methods 0.000 description 8
101150029707 ERBB2 gene Proteins 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
206010058467 Lung neoplasm malignant Diseases 0.000 description 7
108700026244 Open Reading Frames Proteins 0.000 description 7
241000700159 Rattus Species 0.000 description 7
210000003719 b-lymphocyte Anatomy 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000002725 brachytherapy Methods 0.000 description 7
210000000481 breast Anatomy 0.000 description 7
239000000872 buffer Substances 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
230000001413 cellular effect Effects 0.000 description 7
208000029742 colonic neoplasm Diseases 0.000 description 7
230000002596 correlated effect Effects 0.000 description 7
231100000433 cytotoxic Toxicity 0.000 description 7
230000001472 cytotoxic effect Effects 0.000 description 7
230000003247 decreasing effect Effects 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
210000002216 heart Anatomy 0.000 description 7
201000005202 lung cancer Diseases 0.000 description 7
208000020816 lung neoplasm Diseases 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
230000009401 metastasis Effects 0.000 description 7
230000002018 overexpression Effects 0.000 description 7
230000001575 pathological effect Effects 0.000 description 7
238000000746 purification Methods 0.000 description 7
230000002285 radioactive effect Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
208000001333 Colorectal Neoplasms Diseases 0.000 description 6
108020004635 Complementary DNA Proteins 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
102000007079 Peptide Fragments Human genes 0.000 description 6
108010033276 Peptide Fragments Proteins 0.000 description 6
108020004511 Recombinant DNA Proteins 0.000 description 6
208000006265 Renal cell carcinoma Diseases 0.000 description 6
108700019146 Transgenes Proteins 0.000 description 6
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
235000004279 alanine Nutrition 0.000 description 6
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
239000000074 antisense oligonucleotide Substances 0.000 description 6
238000012230 antisense oligonucleotides Methods 0.000 description 6
238000009566 cancer vaccine Methods 0.000 description 6
238000010367 cloning Methods 0.000 description 6
231100000599 cytotoxic agent Toxicity 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
238000002991 immunohistochemical analysis Methods 0.000 description 6
238000002955 isolation Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
206010061289 metastatic neoplasm Diseases 0.000 description 6
230000011987 methylation Effects 0.000 description 6
238000007069 methylation reaction Methods 0.000 description 6
208000023958 prostate neoplasm Diseases 0.000 description 6
238000012552 review Methods 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
238000013518 transcription Methods 0.000 description 6
210000003932 urinary bladder Anatomy 0.000 description 6
230000003442 weekly effect Effects 0.000 description 6
238000001262 western blot Methods 0.000 description 6
108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 5
208000031404 Chromosome Aberrations Diseases 0.000 description 5
108091026890 Coding region Proteins 0.000 description 5
102000053602 DNA Human genes 0.000 description 5
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
102000005720 Glutathione transferase Human genes 0.000 description 5
108010070675 Glutathione transferase Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
238000000636 Northern blotting Methods 0.000 description 5
108091005461 Nucleic proteins Proteins 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
238000004422 calculation algorithm Methods 0.000 description 5
150000001720 carbohydrates Chemical group 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000000973 chemotherapeutic effect Effects 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
230000021615 conjugation Effects 0.000 description 5
230000009089 cytolysis Effects 0.000 description 5
230000007423 decrease Effects 0.000 description 5
239000012636 effector Substances 0.000 description 5
230000008030 elimination Effects 0.000 description 5
238000003379 elimination reaction Methods 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000036039 immunity Effects 0.000 description 5
238000007901 in situ hybridization Methods 0.000 description 5
230000006698 induction Effects 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
238000007918 intramuscular administration Methods 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
230000003211 malignant effect Effects 0.000 description 5
208000010658 metastatic prostate carcinoma Diseases 0.000 description 5
230000003278 mimic effect Effects 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
210000001672 ovary Anatomy 0.000 description 5
238000002823 phage display Methods 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
230000008569 process Effects 0.000 description 5
238000000159 protein binding assay Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
229940063683 taxotere Drugs 0.000 description 5
238000013519 translation Methods 0.000 description 5
238000011277 treatment modality Methods 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 4
102000001301 EGF receptor Human genes 0.000 description 4
108060006698 EGF receptor Proteins 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
108091054437 MHC class I family Proteins 0.000 description 4
108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
108091061960 Naked DNA Proteins 0.000 description 4
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
238000010240 RT-PCR analysis Methods 0.000 description 4
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
108700008625 Reporter Genes Proteins 0.000 description 4
108010084592 Saporins Proteins 0.000 description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
238000010162 Tukey test Methods 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
230000001594 aberrant effect Effects 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000007792 addition Methods 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
229940049706 benzodiazepine Drugs 0.000 description 4
150000001557 benzodiazepines Chemical class 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
231100000504 carcinogenesis Toxicity 0.000 description 4
210000001072 colon Anatomy 0.000 description 4
230000003013 cytotoxicity Effects 0.000 description 4
231100000135 cytotoxicity Toxicity 0.000 description 4
230000002950 deficient Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
208000028715 ductal breast carcinoma in situ Diseases 0.000 description 4
238000002710 external beam radiation therapy Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
238000013537 high throughput screening Methods 0.000 description 4
230000002998 immunogenetic effect Effects 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
201000010982 kidney cancer Diseases 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
238000011068 loading method Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
230000003472 neutralizing effect Effects 0.000 description 4
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
238000004393 prognosis Methods 0.000 description 4
230000004853 protein function Effects 0.000 description 4
230000004850 protein–protein interaction Effects 0.000 description 4
238000011002 quantification Methods 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
235000004400 serine Nutrition 0.000 description 4
239000001509 sodium citrate Substances 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
238000001890 transfection Methods 0.000 description 4
239000004474 valine Substances 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
206010055113 Breast cancer metastatic Diseases 0.000 description 3
125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
206010057248 Cell death Diseases 0.000 description 3
108010047041 Complementarity Determining Regions Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
108010041986 DNA Vaccines Proteins 0.000 description 3
229940021995 DNA vaccine Drugs 0.000 description 3
241000702421 Dependoparvovirus Species 0.000 description 3
238000000729 Fisher's exact test Methods 0.000 description 3
102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
108010074032 HLA-A2 Antigen Proteins 0.000 description 3
102000025850 HLA-A2 Antigen Human genes 0.000 description 3
101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
108010065805 Interleukin-12 Proteins 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 3
206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 3
108091092195 Intron Proteins 0.000 description 3
208000008839 Kidney Neoplasms Diseases 0.000 description 3
238000012313 Kruskal-Wallis test Methods 0.000 description 3
102000043129 MHC class I family Human genes 0.000 description 3
125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
229930012538 Paclitaxel Natural products 0.000 description 3
108010067902 Peptide Library Proteins 0.000 description 3
108091093037 Peptide nucleic acid Proteins 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
208000015634 Rectal Neoplasms Diseases 0.000 description 3
206010038389 Renal cancer Diseases 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
206010046865 Vaccinia virus infection Diseases 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
238000011230 antibody-based therapy Methods 0.000 description 3
210000001106 artificial yeast chromosome Anatomy 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
229930195731 calicheamicin Natural products 0.000 description 3
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000006037 cell lysis Effects 0.000 description 3
239000011651 chromium Substances 0.000 description 3
230000001268 conjugating effect Effects 0.000 description 3
239000000470 constituent Substances 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000002939 deleterious effect Effects 0.000 description 3
201000007273 ductal carcinoma in situ Diseases 0.000 description 3
230000008482 dysregulation Effects 0.000 description 3
210000004602 germ cell Anatomy 0.000 description 3
210000005003 heart tissue Anatomy 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
238000010324 immunological assay Methods 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000002502 liposome Substances 0.000 description 3
238000007726 management method Methods 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
208000037819 metastatic cancer Diseases 0.000 description 3
238000011275 oncology therapy Methods 0.000 description 3
229960001592 paclitaxel Drugs 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000004962 physiological condition Effects 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
206010038038 rectal cancer Diseases 0.000 description 3
201000001275 rectum cancer Diseases 0.000 description 3
208000015347 renal cell adenocarcinoma Diseases 0.000 description 3
210000005084 renal tissue Anatomy 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
230000000391 smoking effect Effects 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
239000007787 solid Substances 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
210000001550 testis Anatomy 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
229940035893 uracil Drugs 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
208000007089 vaccinia Diseases 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
108010066676 Abrin Proteins 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
206010048610 Cardiotoxicity Diseases 0.000 description 2
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108090000994 Catalytic RNA Proteins 0.000 description 2
102000053642 Catalytic RNA Human genes 0.000 description 2
206010008805 Chromosomal abnormalities Diseases 0.000 description 2
108700010070 Codon Usage Proteins 0.000 description 2
108091029523 CpG island Proteins 0.000 description 2
108091029430 CpG site Proteins 0.000 description 2
229920001076 Cutan Polymers 0.000 description 2
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
230000004544 DNA amplification Effects 0.000 description 2
108010092160 Dactinomycin Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
241000701024 Human betaherpesvirus 5 Species 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
102000004310 Ion Channels Human genes 0.000 description 2
108090000862 Ion Channels Proteins 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
241000713666 Lentivirus Species 0.000 description 2
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
108091054438 MHC class II family Proteins 0.000 description 2
206010027452 Metastases to bone Diseases 0.000 description 2
206010027459 Metastases to lymph nodes Diseases 0.000 description 2
229930192392 Mitomycin Natural products 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
244000061176 Nicotiana tabacum Species 0.000 description 2
235000002637 Nicotiana tabacum Nutrition 0.000 description 2
238000010222 PCR analysis Methods 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000037062 Polyps Diseases 0.000 description 2
206010071019 Prostatic dysplasia Diseases 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
230000037453 T cell priming Effects 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
238000002679 ablation Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
239000002870 angiogenesis inducing agent Substances 0.000 description 2
238000011319 anticancer therapy Methods 0.000 description 2
239000003972 antineoplastic antibiotic Substances 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
239000012867 bioactive agent Substances 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
208000035269 cancer or benign tumor Diseases 0.000 description 2
239000002775 capsule Substances 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
231100000259 cardiotoxicity Toxicity 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000004186 co-expression Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
229960003901 dacarbazine Drugs 0.000 description 2
229960000975 daunorubicin Drugs 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
230000017858 demethylation Effects 0.000 description 2
238000010520 demethylation reaction Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
229940082789 erbitux Drugs 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
238000002825 functional assay Methods 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
238000001476 gene delivery Methods 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
230000002055 immunohistochemical effect Effects 0.000 description 2
230000001024 immunotherapeutic effect Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
230000004807 localization Effects 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
238000013411 master cell bank Methods 0.000 description 2
229960004961 mechlorethamine Drugs 0.000 description 2
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
238000007855 methylation-specific PCR Methods 0.000 description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
239000013642 negative control Substances 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
229910052759 nickel Inorganic materials 0.000 description 2
238000010606 normalization Methods 0.000 description 2
238000005457 optimization Methods 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
229960003171 plicamycin Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
201000001514 prostate carcinoma Diseases 0.000 description 2
230000009145 protein modification Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000003753 real-time PCR Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000010845 search algorithm Methods 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
210000000582 semen Anatomy 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
238000009121 systemic therapy Methods 0.000 description 2
238000012353 t test Methods 0.000 description 2
229960001603 tamoxifen Drugs 0.000 description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
229960001278 teniposide Drugs 0.000 description 2
235000008521 threonine Nutrition 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000009466 transformation Effects 0.000 description 2
206010044412 transitional cell carcinoma Diseases 0.000 description 2
230000032258 transport Effects 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
230000005747 tumor angiogenesis Effects 0.000 description 2
230000004565 tumor cell growth Effects 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
206010061728 Bone lesion Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241001092081 Carpenteria Species 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000052052 Casein Kinase II Human genes 0.000 description 1
108010010919 Casein Kinase II Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000000989 Complement System Proteins Human genes 0.000 description 1
108010069112 Complement System Proteins Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
108700032819 Croton tiglium crotin II Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
101710096438 DNA-binding protein Proteins 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000672609 Escherichia coli BL21 Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
208000000666 Fowlpox Diseases 0.000 description 1
102100039554 Galectin-8 Human genes 0.000 description 1
108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
229940123011 Growth factor receptor antagonist Drugs 0.000 description 1
241000696272 Gull adenovirus Species 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
108010035452 HLA-A1 Antigen Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 1
101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
108010028921 Lipopeptides Proteins 0.000 description 1
208000007433 Lymphatic Metastasis Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
208000035346 Margins of Excision Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
206010027458 Metastases to lung Diseases 0.000 description 1
206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
108090000143 Mouse Proteins Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
241000283283 Orcinus orca Species 0.000 description 1
241000282579 Pan Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010043958 Peptoids Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
102100038124 Plasminogen Human genes 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
101800001357 Potential peptide Proteins 0.000 description 1
102400000745 Potential peptide Human genes 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
101710195626 Transcriptional activator protein Proteins 0.000 description 1
206010066901 Treatment failure Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
108010015780 Viral Core Proteins Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000012452 Xenomouse strains Methods 0.000 description 1
PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
238000010317 ablation therapy Methods 0.000 description 1
229930183665 actinomycin Natural products 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
108700025316 aldesleukin Proteins 0.000 description 1
229960005310 aldesleukin Drugs 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
108010001818 alpha-sarcin Proteins 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229940037003 alum Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
LXQXZNRPTYVCNG-YPZZEJLDSA-N americium-241 Chemical compound [241Am] LXQXZNRPTYVCNG-YPZZEJLDSA-N 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000003491 array Methods 0.000 description 1
210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000002820 assay format Methods 0.000 description 1
108010044540 auristatin Proteins 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
229960002756 azacitidine Drugs 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000003766 bioinformatics method Methods 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
238000000339 bright-field microscopy Methods 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000012219 cassette mutagenesis Methods 0.000 description 1
230000008568 cell cell communication Effects 0.000 description 1
230000023402 cell communication Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
229940030156 cell vaccine Drugs 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
229940030792 clinac Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
238000012926 crystallographic analysis Methods 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
229960005501 duocarmycin Drugs 0.000 description 1
229930184221 duocarmycin Natural products 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
108010028531 enomycin Proteins 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000008029 eradication Effects 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
201000010255 female reproductive organ cancer Diseases 0.000 description 1
210000004996 female reproductive system Anatomy 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
229960000961 floxuridine Drugs 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
239000012530 fluid Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
230000009368 gene silencing by RNA Effects 0.000 description 1
230000037442 genomic alteration Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
PCHJSUWPFVWCPO-OUBTZVSYSA-N gold-198 Chemical compound [198Au] PCHJSUWPFVWCPO-OUBTZVSYSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000003862 health status Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229920000140 heteropolymer Polymers 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
150000002411 histidines Chemical class 0.000 description 1
238000010231 histologic analysis Methods 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
102000052972 human La Human genes 0.000 description 1
210000002758 humerus Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
150000001469 hydantoins Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
229940097277 hygromycin b Drugs 0.000 description 1
230000006607 hypermethylation Effects 0.000 description 1
230000014200 hypermethylation of CpG island Effects 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
238000009802 hysterectomy Methods 0.000 description 1
229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
239000012642 immune effector Substances 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
229940124452 immunizing agent Drugs 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000012151 immunohistochemical method Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
208000030776 invasive breast carcinoma Diseases 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
238000004969 ion scattering spectroscopy Methods 0.000 description 1
GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000002523 lectin Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000001325 log-rank test Methods 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000012976 mRNA stabilization Effects 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
229960001786 megestrol Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
108010010621 modeccin Proteins 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
230000009149 molecular binding Effects 0.000 description 1
ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
230000007498 myristoylation Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
230000017095 negative regulation of cell growth Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
229940023146 nucleic acid vaccine Drugs 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000011164 ossification Effects 0.000 description 1
230000001582 osteoblastic effect Effects 0.000 description 1
230000000010 osteolytic effect Effects 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
229960001744 pegaspargase Drugs 0.000 description 1
108010001564 pegaspargase Proteins 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
108010076042 phenomycin Proteins 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
229960000952 pipobroman Drugs 0.000 description 1
YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
108010054442 polyalanine Proteins 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
210000004986 primary T-cell Anatomy 0.000 description 1
230000037452 priming Effects 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000013930 proline Nutrition 0.000 description 1
125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
210000005267 prostate cell Anatomy 0.000 description 1
208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
238000011471 prostatectomy Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000002331 protein detection Methods 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
239000000649 purine antagonist Substances 0.000 description 1
239000003790 pyrimidine antagonist Substances 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
150000003235 pyrrolidines Chemical class 0.000 description 1
238000009801 radical cystectomy Methods 0.000 description 1
238000011472 radical prostatectomy Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000002601 radiography Methods 0.000 description 1
229910052705 radium Inorganic materials 0.000 description 1
HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
229910052704 radon Inorganic materials 0.000 description 1
SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
230000022983 regulation of cell cycle Effects 0.000 description 1
208000010639 renal pelvis urothelial carcinoma Diseases 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000003571 reporter gene assay Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000013515 script Methods 0.000 description 1
230000009991 second messenger activation Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
150000003355 serines Chemical class 0.000 description 1
230000036299 sexual function Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000004055 small Interfering RNA Substances 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000010907 stover Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
229960005353 testolactone Drugs 0.000 description 1
BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
150000003588 threonines Chemical class 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
229960005267 tositumomab Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
239000000439 tumor marker Substances 0.000 description 1
230000001173 tumoral effect Effects 0.000 description 1
238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
238000003160 two-hybrid assay Methods 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
150000003668 tyrosines Chemical class 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000009808 unilateral salpingo-oophorectomy Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
229960001055 uracil mustard Drugs 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
201000000334 ureter transitional cell carcinoma Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
239000002699 waste material Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

CA2742088A 2004-05-28 2005-05-17 Anticorps qui lient les proteines psca pour le diagnostic du cancer Abandoned CA2742088A1 (fr)

Applications Claiming Priority (15)

Application Number	Priority Date	Filing Date	Title
US10/857,484		2004-05-28
USPCT/US2004/017231		2004-05-28
US10/857,484 US7622564B2 (en)	2003-05-30	2004-05-28	Prostate stem cell antigen (PSCA) variants and subsequences thereof
PCT/US2004/017231 WO2005014780A2 (fr)	2003-05-30	2004-05-28	Variants de l'antigene de cellules souches de la prostate (psca) et utilisations subsequentes de ceux-ci
US61638104P	2004-10-05	2004-10-05
US60/616,381		2004-10-05
US61788104P	2004-10-12	2004-10-12
US60/617,881		2004-10-12
US62131004P	2004-10-21	2004-10-21
US60/621,310		2004-10-21
US63307704P	2004-12-02	2004-12-02
US60/633,077		2004-12-02
US67200005P	2005-04-14	2005-04-14
US60/672,000		2005-04-14
CA2567449A CA2567449C (fr)	2004-05-28	2005-05-17	Anticorps et molecules apparentees qui se lient aux proteines d'antigene des cellules souches de prostate (proteines de psca)

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2567449A Division CA2567449C (fr)	2004-05-28	2005-05-17	Anticorps et molecules apparentees qui se lient aux proteines d'antigene des cellules souches de prostate (proteines de psca)

Publications (1)

Publication Number	Publication Date
CA2742088A1 true CA2742088A1 (fr)	2005-12-15

Family

ID=38252219

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2742088A Abandoned CA2742088A1 (fr)	2004-05-28	2005-05-17	Anticorps qui lient les proteines psca pour le diagnostic du cancer

Country Status (3)

Country	Link
CN (1)	CN1997751B (fr)
CA (1)	CA2742088A1 (fr)
ZA (1)	ZA200609894B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN117736295A (zh) *	2024-02-21	2024-03-22	中国科学院烟台海岸带研究所	一种凝集素及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW202003564A (zh) *	2018-03-24	2020-01-16	美商再生元醫藥公司	用於產生抗肽-mhc複合物之治療性抗體的經基因修飾的非人類動物、其製法與用途
CN112820355B (zh) *	2020-12-16	2024-03-22	浙江工业大学	一种基于蛋白质序列比对的分子虚拟筛选方法
CN113287569B (zh) *	2021-05-27	2023-04-07	四川康城生物科技有限公司	一种免疫低下动物模型的构建方法
CN113604505A (zh) *	2021-08-11	2021-11-05	华农（肇庆）生物产业技术研究院有限公司	pSFV-p32病毒样颗粒及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4243187B2 (ja) *	2001-09-07	2009-03-25	ポリマンサイエンティフィックイミューンバイオロジッシュフォーシュングゲゼルシャフトミットベシュレンクテルファフツング	ＨＩＶ−１のｇｐ４１のクリプティックエピトープを模倣するペプチド

2005
- 2005-05-17 CN CN200580017239.9A patent/CN1997751B/zh active Active
- 2005-05-17 CA CA2742088A patent/CA2742088A1/fr not_active Abandoned
2006
- 2006-11-27 ZA ZA200609894A patent/ZA200609894B/xx unknown

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN117736295A (zh) *	2024-02-21	2024-03-22	中国科学院烟台海岸带研究所	一种凝集素及其应用

Also Published As

Publication number	Publication date
CN1997751A (zh)	2007-07-11
CN1997751B (zh)	2012-08-29
ZA200609894B (en)	2008-01-30

Legal Events

Date	Code	Title	Description
2011-11-15	EEER	Examination request
2017-03-22	FZDE	Discontinued	Effective date: 20170208

Publication	Publication Date	Title
US8278424B2 (en)	2012-10-02	Antibodies that bind to PSCA proteins for diagnosis of cancer
US8013128B2 (en)	2011-09-06	Antibodies and related molecules that bind to PSCA proteins
US8206932B2 (en)	2012-06-26	Antibodies and related molecules that bind to PSCA proteins
US7427399B2 (en)	2008-09-23	Antibodies and related molecules that bind to 161P2F10B proteins
EP2185574B1 (fr)	2013-05-08	Anticorps et molécules apparentées qui se lient aux protéines 24p4c12
US8039597B2 (en)	2011-10-18	Antibodies and related molecules that bind to 24P4C12 proteins
CA2567449C (fr)	2014-03-11	Anticorps et molecules apparentees qui se lient aux proteines d'antigene des cellules souches de prostate (proteines de psca)
US8236310B2 (en)	2012-08-07	Antibodies and related molecules that bind to 161P2F10B proteins
IL214210A (en)	2013-01-31	Antibodies that bind to PSCA proteins for cancer diagnosis
AU2006237616B2 (en)	2012-03-22	Antibodies and related molecules that bind to PSCA proteins
US20090068098A1 (en)	2009-03-12	Antibodies and related molecules that bind to 58p1d12 proteins
CA2742088A1 (fr)	2005-12-15	Anticorps qui lient les proteines psca pour le diagnostic du cancer
US8350009B2 (en)	2013-01-08	Antibodies and related molecules that bind to 161P2F10B proteins
US20100047166A1 (en)	2010-02-25	Antibodies and related molecules that bind to 58p1d12 proteins
DK1753871T3 (en)	2015-10-19	Antibodies and related molecules that bind to psca proteins
WO2010022279A1 (fr)	2010-02-25	Anticorps et molécules associées qui se lient à des protéines 58p1d12

CA2742088A1 - Anticorps qui lient les proteines psca pour le diagnostic du cancer - Google Patents

Info

Links

Classifications

Applications Claiming Priority (15)

Related Parent Applications (1)

Publications (1)

Family

ID=38252219

Family Applications (1)

Country Status (3)

Cited By (1)

Families Citing this family (4)

Family Cites Families (1)

Cited By (1)

Also Published As

Similar Documents

Legal Events